Physicians' Academy for Cardiovascular Education

GLP-1 analogue reduces the risk of major adverse cardiovascular events in type 2 diabetes

News - Mar. 7, 2016

Liraglutide significantly reduces the risk of major adverse cardiovascular events in the LEADER trial. The LEADER trial investigated the cardiovascular safety of liraglutide over a period of up to 5 years in more than 9,000 adults with type 2 diabetes at high risk of major adverse cardiovascular events. The trial compared the addition of either liraglutide or placebo to standard of care and met the primary endpoint of showing non-inferiority as well as demonstrating superiority, with a statistically significant reduction in cardiovascular risk. The primary endpoint of the study was defined as the composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. The superior reduction of major adverse cardiovascular events demonstrated by liraglutide was derived from all three components of the endpoint.  

Liraglutide is a human glucagon-like peptide-1 (GLP-1) analogue with an amino acid sequence 97% similar to endogenous human GLP-1. In Europe, liraglutide is indicated for treatment of adults with type 2 diabetes to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. Liraglutide was approved by the U.S. Food and Drug Administration in 2010, as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes.

The safety profile of liraglutide in LEADER was generally consistent with previous liraglutide clinical studies.  The detailed results are planned to be presented at the 76th Scientific Sessions of the American Diabetes Association in June 2016. 


Press release Novo Nordisk March 4, 2016

Share this page with your colleagues and friends: